Study Results - ClinicalTrials NCT00712348

Results from Study PB-06-002, ‘A Phase 3 Multicenter, Open-label, Switchover Trial to Assess the Safety and Efficacy of Plant Cell Expressed Recombinant Human Glucocerebrosidase (Taliglucerase alfa) in Patients with GD Treated with Imiglucerase (Cerezyme®) Enzyme Replacement Therapy.’ Adult and pediatric patients (N=26 and 5, respectively) with a total treatment duration of 9 months (study started on December 2008 and ended January 2013). Results available at ClinicalTrials.gov: NCT00712348. Please acknowledge the National Library of Medicine (NLM) in subsequent use of this document. While using these results please cite the study in PLOS One and acknowledge the National Library of Medicine.